MAPT and Alzheimer disease: For example, inhibition of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), a regulator of inflammation, cytokine release, and necroptotic cell death, is being investigated as treatment for AD, ALS, and multiple sclerosis (MS) [30], while tau protein is being targeted with antibodies for both progressive supranuclear palsy (PSP) and AD [31].